For the quarter ended March 2025, News Corp. (NWSA) reported revenue of $2.01 billion, down 17.1% over the same period last year. EPS came in at $0.17, compared to $0.11 in the year-ago quarter. The reported revenue represents a surprise of -0.29% over the Zacks Consensus Estimate of $2.01 billion. With the consensus EPS estimate being $0.19, the EPS surprise was -10.53%. While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall Street expectations to determine th ...

Hub Group (HUBG) reported $915.22 million in revenue for the quarter ended March 2025, representing a year-over-year decline of 8.4%. EPS of $0.44 for the same period compares to $0.44 a year ago. Here is how Hub Group performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts: View all Key Company Metrics for Hub Group here>>> Shares of Hub Group have returned -10.4% over the past month versus the Zacks S&P 500 composite's +11.3% change. The s ...

Since these metrics play a crucial role in driving the top- and bottom-line numbers, comparing them with the year-ago numbers and what analysts estimated about them helps investors better project a stock's price performance. Here is how Figs performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts: Figs (FIGS) reported $124.9 million in revenue for the quarter ended March 2025, representing a year-over-year increase of 4.7%. EPS of $0.00 for ...

Core Insights - McKesson reported revenue of $90.82 billion for the quarter ended March 2025, reflecting a 19% increase year-over-year, with EPS at $10.12 compared to $6.18 in the same quarter last year [1] - The revenue fell short of the Zacks Consensus Estimate of $93.7 billion by 3.08%, while the EPS exceeded the consensus estimate of $9.81 by 3.16% [1] Revenue Breakdown - U.S. Pharmaceutical revenue was $83.17 billion, a 20.9% increase year-over-year, but below the average estimate of $85.79 billion [4] - Prescription Technology Solutions revenue reached $1.34 billion, up 13.5% year-over-year, slightly below the average estimate of $1.36 billion [4] - International revenue was $3.46 billion, showing a year-over-year decline of 2.5%, compared to the average estimate of $3.55 billion [4] - Medical-Surgical Solutions revenue was $2.85 billion, a 0.6% increase year-over-year, exceeding the average estimate of $2.79 billion [4] Adjusted Operating Profit - Adjusted Operating Profit for U.S. Pharmaceutical was $1.05 billion, matching the average estimate [4] - Adjusted Operating Profit for International was $102 million, surpassing the average estimate of $96.42 million [4] - Adjusted Operating Profit for Corporate was -$165 million, slightly worse than the average estimate of -$160.18 million [4] - Adjusted Operating Profit for Prescription Technology Solutions was $285 million, exceeding the average estimate of $267.80 million [4] - Adjusted Operating Profit for Medical-Surgical Solutions was $285 million, slightly above the average estimate of $283.33 million [4] Stock Performance - McKesson's shares returned +7.5% over the past month, underperforming compared to the Zacks S&P 500 composite's +11.3% change [3] - The stock currently holds a Zacks Rank 3 (Hold), indicating potential performance in line with the broader market in the near term [3]

Arlo Technologies (ARLO) reported $119.07 million in revenue for the quarter ended March 2025, representing a year-over-year decline of 4.1%. EPS of $0.15 for the same period compares to $0.09 a year ago. Here is how Arlo Technologies performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts: View all Key Company Metrics for Arlo Technologies here>>> Shares of Arlo Technologies have returned +10.3% over the past month versus the Zacks S&P 500 ...

For the quarter ended March 2025, DoubleVerify Holdings (DV) reported revenue of $165.06 million, up 17.3% over the same period last year. EPS came in at $0.01, compared to $0.04 in the year-ago quarter. View all Key Company Metrics for DoubleVerify here>>> Shares of DoubleVerify have returned +1.3% over the past month versus the Zacks S&P 500 composite's +11.3% change. The stock currently has a Zacks Rank #4 (Sell), indicating that it could underperform the broader market in the near term. Revenue by custo ...

Over the last four quarters, the company has surpassed consensus EPS estimates three times. TransMedics, which belongs to the Zacks Medical - Instruments industry, posted revenues of $143.54 million for the quarter ended March 2025, surpassing the Zacks Consensus Estimate by 16.17%. This compares to year- ago revenues of $96.85 million. The company has topped consensus revenue estimates three times over the last four quarters. The sustainability of the stock's immediate price movement based on the recently- ...

Sutro Biopharma, Inc. (STRO) came out with a quarterly loss of $0.91 per share versus the Zacks Consensus Estimate of a loss of $0.63. This compares to loss of $0.95 per share a year ago. These figures are adjusted for non-recurring items. This quarterly report represents an earnings surprise of -44.44%. A quarter ago, it was expected that this company would post a loss of $0.86 per share when it actually produced a loss of $0.89, delivering a surprise of -3.49%. Over the last four quarters, the company has ...

Willdan Group (WLDN) came out with quarterly earnings of $0.63 per share, beating the Zacks Consensus Estimate of $0.44 per share. This compares to earnings of $0.40 per share a year ago. These figures are adjusted for non-recurring items. This quarterly report represents an earnings surprise of 43.18%. A quarter ago, it was expected that this energy efficiency and sustainability consultant would post earnings of $0.57 per share when it actually produced earnings of $0.75, delivering a surprise of 31.58%. O ...

Retirement is complicated and you only get once chance to do it right. Don't miss out because you didn't know what was out there.The Retirement Forum provides actionable ideals, a high-yield safe retirement portfolio, and macroeconomic outlooks, all to help you maximize your capital and your income. We search the entire market to help you maximize returns.The Value Portfolio specializes in building retirement portfolios and utilizes a fact-based research strategy to identify investments. This includes exten ...